A practical reference on Aggregation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Reconstitution is often performed with sterile water, buffer, or a water-miscible organic solvent, depending on solubility. The solvent should be added gently along the vial wall, and the solution mixed by gentle swirling rather than vigorous vortexing, which can cause foaming and surface denaturation. Some sequences require a small amount of base or acid to dissolve, followed by pH adjustment. Preparing a concentrated stock solution can simplify later dilution, but the stock itself may have limited stability. Records of solvent, concentration, and date support reproducibility.
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
| Property | Value | Notes |
|---|---|---|
| Appearance (lyophilized powder) | White to off-white powder | Color varies with sequence, counterion, and residual solvent. |
| Solubility | Aqueous or organic depending on sequence | Hydrophobic peptides may require organic co-solvents. |
| Typical storage temperature (dry) | -20 °C or lower | -80 °C is used for long-term archival storage. |
| Common analytical method | Reversed-phase HPLC | Purity and identity are assessed by retention time and peak area. |
| Common synonyms | Peptide, oligopeptide, polypeptide | Usage varies with chain length and context. |
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Moisture, oxygen, and light also affect peptide integrity. Lyophilized powders absorb water from the air, which can enable hydrolysis and conformational changes. Oxygen promotes oxidation of sensitive residues, so storage under inert gas or in sealed vials is common. Light exposure can cause photodegradation, particularly for peptides containing aromatic amino acids. Buffer choice and pH influence charge state and solubility; extremes of pH accelerate deamidation and hydrolysis. Adding stabilizers such as sugars or polyols can protect the peptide during freezing and drying. Optimal conditions are determined empirically for each peptide.
Peptides are short chains of amino acids that can undergo both chemical and physical degradation. Chemical pathways include hydrolysis of peptide bonds, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and isomerization of aspartate. Physical instability leads to aggregation, precipitation, or adsorption to surfaces. The rate of these processes depends on the peptide sequence, the formulation, and the storage environment. Because each peptide has a unique composition, no single storage condition applies to all peptides. Stability studies are therefore conducted to define suitable conditions for each specific molecule.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
Temperature is the most common controlled variable, but its effect is not linear. Lower temperatures reduce most chemical reaction rates, yet freezing can concentrate solutes and create pH shifts in the remaining liquid phase. Repeated freeze-thaw cycles can denature or aggregate some peptides, especially those with hydrophobic segments. For lyophilized powders, desiccation and protection from moisture are often more important than deep freezing. For solutions, the choice between refrigeration and freezing depends on peptide concentration, buffer components, and the intended duration of storage.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, conformation, and the surrounding matrix. In the solid state, lyophilized powders are generally more stable than solutions because low water activity slows hydrolysis and oxidation. Residual moisture, oxygen, trace metals, and light can still promote degradation over time. Storage recommendations therefore balance temperature, humidity, and container integrity rather than relying on a single condition. The optimal condition for a given peptide is often determined empirically because no universal rule covers every sequence.
=== Hysteresis === Hysteresis, in this case, refers to the restructuring of the adhesive interface over some period of time, with the result being that the work needed to separate two surfaces is greater than the work that was gained by bringing them together (W > γ1 + γ2). For the most part, this is a phenomenon associated with diffusive bonding. The more time is given for a pair of surfaces exhibiting diffusive bonding to restructure, the more diffusion will occur, the stronger the adhesion will become. The aforementioned reaction of certain polymer-on-polymer surfaces to ultraviolet radiation and oxygen gas is an instance of hysteresis, but it will also happen over time without those factors. In addition to being able to observe hysteresis by determining if W > γ1 + γ2 is true, one can also find evidence of it by performing "stop-start" measurements. In these experiments, two surfaces slide against one another continuously and occasionally stopped for some measured amount of time. Results from experiments on polymer-on-polymer surfaces show that if the stopping time is short enough, resumption of smooth sliding is easy. If, however, the stopping time exceeds some limit, there is an initial increase of resistance to motion, indicating that the stopping time was sufficient for the surfaces to restructure.
== Commercially significant benzophenones == The >300 natural benzophenones exhibit great structural diversity and biological activities. 2-Amino-5-chlorobenzophenone is used in the synthesis of benzodiazepines. Substituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreens. Their use has been criticized (see sunscreen controversy). Michler's ketone has dimethylamino substituents at each para position. The high-strength polymer PEEK is generated from 4,4'-difluorobenzophenone. 4,4′-Dihydroxybenzophenone is also of interest in this context. 4-Chloro-4'-hydroxybenzophenone is used to make related polymers.
=== Direct Xa inhibitors in clinical trials === Rivaroxaban, apixaban, edoxaban and betrixaban are already on the market. As of October 2016, several new direct Xa inhibitors have entered clinical trials. These are letaxaban from Takeda and eribaxaban from Pfizer.
== Function == This gene encodes a selenoprotein, which contains a selenocysteine (Sec) residue at its active site. The selenocysteine is encoded by the UGA codon that normally signals translation termination. The 3' UTR of selenoprotein genes have a common stem-loop structure, the sec insertion sequence (SECIS), that is necessary for the recognition of UGA as a Sec codon rather than as a stop signal. Studies in mouse suggest that this selenoprotein may have redox function and may be involved in the quality control of protein folding.
Sources: en.wikipedia.org
== Biological function and disease relevance == In E. coli, OmpT is a housekeeping protease that degrades foreign peptide material that the bacteria encounters. Because of its ability to cleave peptides present in its surrounding environment, OmpT is associated with several pathologies.
In terms of geographic focus, while the Marshall Plan and Point Four mainly operated in different countries, the Marshall Plan also expanded into developing nations. In particular, the Marshall Plan financed activities in:
== Medical uses == Probenecid is primarily used to treat gout and hyperuricemia. Probenecid is sometimes used to increase the concentration of some antibiotics and to protect the kidneys when given with cidofovir. Specifically, a small amount of evidence supports the use of intravenous cefazolin once rather than three times a day when it is combined with probenecid. It has also found use as a masking agent, potentially helping athletes using performance-enhancing substances to avoid detection by drug tests.
=== Continued employment by the Astros === As part of a personal services contract Bagwell signed with the Astros, he served as a coach in spring training of 2007. On July 11, 2010, the Astros hired Bagwell to be their hitting coach, replacing Sean Berry. At the time of the switch, the Astros had the second-worst average (.237) in the majors and the worst OBP (.295). At the end of the season, the team marginally improved, but was still last in the league in OBP (.303) and SLG (.362) and Bagwell announced he would not return as hitting coach. After a five-year gap in contact with the Astros organization, Bagwell accepted a formal invitation from manager A. J. Hinch to be a guest instructor in spring training of 2015. He is currently a special advisor to team owner Jim Crane.
=== Discovery of PI-3-kinase and PtdIns(3,4)P2 === In a series of studies spanning several years, Cantley and colleagues demonstrated that a kinase activity associated with the middle T oncoprotein is a phosphoinositide kinase, that it is a novel type of phosphoinositide kinase that phosphorylates the 3' position on the inositol ring, and that this phosphatidylinositol-3-kinase (PI-3-kinase) is activated by growth factors to produce novel 3'-phosphorylated phosphoinositides, in particularly PtdIns(3,4,5)P3 that had previously been identified in physiologically stimulated human neutrophils. In subsequent years Cantley and colleagues identified critical aspects of the regulation of PI-3-kinase by growth factor receptors. Specifically, they discovered that the catalytic subunit p110 dimerizes with the regulatory subunit p85, and that the SH2 domain of p85 specifically recognized phosphotyrosines on growth factor receptors or adaptor proteins via the pY-X-X-M motif. The Cantley lab has also made seminal contributions to understanding signaling downstream of PI-3-kinase. They discovered that the Pleckstrin Homology domain of AKT binds to PtdIns(3,4,5)P3 (and PtdIns(3,4)P2) and that this binding is critical for activation of AKT catalytic activity. They further demonstrated that tuberin/TSC2 is a critical substrate of AKT, and together with the laboratory of John Blenis they discovered that AKT phosphorylation of tuberin/TSC2 is required for activation of mTOR TORC1 kinase activity via regulation of the small GTPase rheb.
Sources: en.wikipedia.org
Most are bound to thyroxine-binding globulin (about 70%), transthyretin (10%), and albumin (15%). Only the 0.03% of T4 and 0.3% of T3 traveling freely have hormonal activity. In addition, up to 85% of the T3 in blood is produced following conversion from T4 by iodothyronine deiodinases in organs around the body. Thyroid hormones act by crossing the cell membrane and binding to intracellular nuclear thyroid hormone receptors TR-α1, TR-α2, TR-β1, and TR-β2, which bind with hormone response elements and transcription factors to modulate DNA transcription. In addition to these actions on DNA, the thyroid hormones also act within the cell membrane or within cytoplasm via reactions with enzymes, including calcium ATPase, adenylyl cyclase, and glucose transporters.
== Production == Bang was cast in the lead role despite not speaking French, as von Spreckelsen himself was not a French speaker, and carefully rehearsed the script to ensure that he would be able to perform it.
In 1912, Frederick Gowland Hopkins demonstrated that unknown accessory factors found in milk, other than carbohydrates, proteins, and fats were necessary for growth in rats. Hopkins received a Nobel Prize for this discovery in 1929. By 1913, one of these substances was independently discovered by Elmer McCollum and Marguerite Davis at the University of Wisconsin–Madison, and Lafayette Mendel and Thomas Burr Osborne at Yale University. McCollum and Davis ultimately received credit because they submitted their paper three weeks before Mendel and Osborne. Both papers appeared in the same issue of the Journal of Biological Chemistry in 1913. The "accessory factors" were termed "fat soluble" in 1918, and later "vitamin A" in 1920. In 1919, Harry Steenbock (University of Wisconsin–Madison) proposed a relationship between yellow plant pigments (β-carotene) and vitamin A. In 1931, Swiss chemist Paul Karrer described the chemical structure of vitamin A. Retinoic acid and retinol were first synthesized in 1946 and 1947 by two Dutch chemists, David Adriaan van Dorp and Jozef Ferdinand Arens.
Seeing an opportunity in Napoleon I's historic defeat, Prussia, Sweden and several other German states switched sides, joining Russia, the United Kingdom and others opposing Napoleon. Napoleon vowed that he would create a new army as large as the one he had sent into Russia, and quickly built up his forces in the east from 30,000 to 130,000 and eventually to 400,000. Napoleon inflicted 40,000 casualties on the Allies at Lützen (2 May 1813) and Bautzen (20–21 May 1813). Both battles involved forces of over 250,000, making them some of the largest conflicts of the wars so far. Klemens von Metternich in November 1813 offered Napoleon the Frankfurt proposals. They would allow Napoleon to remain Emperor but France would be reduced to its "natural frontiers" and lose control of most of Italy and Germany and the Netherlands. Napoleon still expected to win the wars, and rejected the terms. By 1814, as the Allies were closing in on Paris, Napoleon I did agree to the Frankfurt proposals, but it was too late and he rejected the new harsher terms proposed by the Allies.
Glutathione S-transferases (GSTs), previously known as ligandins, are a family of eukaryotic and prokaryotic phase II metabolic isozymes best known for their ability to catalyze the conjugation of the reduced form of glutathione (GSH) to xenobiotic substrates for the purpose of detoxification. The GST family consists of three superfamilies: the cytosolic, mitochondrial, and microsomal—also known as MAPEG—proteins. Members of the GST superfamily are extremely diverse in amino acid sequence, and a large fraction of the sequences deposited in public databases are of unknown function. The Enzyme Function Initiative (EFI) is using GSTs as a model superfamily to identify new GST functions. GSTs can constitute up to 10% of cytosolic protein in some mammalian organs. GSTs catalyse the conjugation of GSH—via a sulfhydryl group—to electrophilic centers on a wide variety of substrates in order to make the compounds more water-soluble. This activity detoxifies endogenous compounds such as peroxidised lipids and enables the breakdown of xenobiotics. GSTs may also bind toxins and function as transport proteins, which gave rise to the early term for GSTs, ligandin.
Sources: en.wikipedia.org
Freezing slows hydrolysis and oxidation by reducing molecular motion and available water. Lyophilized powders contain little moisture, so they can remain stable for extended periods when kept cold and dry. The exact temperature depends on peptide sequence and expected storage duration.
Solutions generally degrade faster because water participates in hydrolysis and enables aggregation or microbial growth. Buffer composition, pH, and concentration influence the rate. For this reason, many procedures prepare solutions shortly before use and avoid long-term liquid storage.
Ice crystal formation and concentrated solutes can stress peptide molecules and promote aggregation. Repeated cycling also exposes the sample to temperature fluctuations that may accelerate degradation. Aliquoting before freezing reduces the number of cycles a single container experiences.
Dividing a stock into single-use portions usually reduces multiple thawing and refreezing events and lowers contamination risk. It also allows a needed amount to be removed without warming the entire supply.